Vor Biopharma Inc.
VOR
$23.66
-$1.44-5.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 96.01% | -575.94% | 5,709.72% | -2,848.89% | -5,552.75% |
| Total Depreciation and Amortization | -98.23% | -96.61% | -97.34% | -99.76% | 134.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -98.15% | 5,988.80% | -59,023.25% | 21,307.24% | 41,133.35% |
| Change in Net Operating Assets | 94.71% | -489.08% | 12.22% | 5,208.08% | 228.76% |
| Cash from Operations | 27.87% | -23.11% | 5.24% | -130.46% | -61.05% |
| Capital Expenditure | 21.05% | 79.22% | -336.11% | -617.65% | -1,588.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3,641,300.00% | -26,319,000.00% | -- | -- | -100.00% |
| Cash from Investing | -5,755.42% | -114,350.87% | -67,919.44% | -617.65% | -98.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.91% | -- | 768.21% | 19,909.91% | 385.00% |
| Repurchase of Common Stock | 93.75% | 96.36% | -393.33% | 72.86% | 37.25% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.06% | 76.95% | -7,432.52% | -- | -- |
| Cash from Financing | -100.06% | 12,454.79% | 477.64% | 52,458.54% | 564,825.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -144.13% | -610.34% | 709.66% | -39.00% | 351.68% |